Abstract
Gastric mucous glycoproteins (GMGs) are an important protective component of the gastric 'mucus bicarbonate barrier'. The characterization of drug effects on GMG metabolism is difficult because the quantification of GMGs poses analytical problems and because indirect drug effects (e.g. on other gastric secretory functions) can influence GMG metabolism or quantification and thereby complicate the interpretation of in-vivo experiments. The use of suitable in-vitro systems, in particular of isolated gastric mucous cells, helped to resolve the latter problem and enabled the characterization of direct effects of prostaglandins, gastric acid secretagogues, peptide hormones, growth factors, adrenoceptor agonists, and synthetic compounds (e.g. teprenone) on GMG metabolism. Furthermore, from these experiments, evidence has accumulated that the cyclic AMP system, the inositol trisphosphate/calcium/protein kinase C system and the cyclic GMP system are involved in the intracellular transmission of drug effects on GMG metabolism.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: European Journal of Gastroenterology & Hepatology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
